Brief: Oncorus Reports Data From Its Ongoing Phase 1 Clinical Study Of ONCR-177, At SITC 2021
12/11/2021 12:49
Nov 12 (Reuters) - Oncorus Inc ONCR.O :
* ONCORUS REPORTS INITIAL SAFETY, TOLERABILITY, IMMUNE
ACTIVATION
AND POSITIVE CLINICAL RESPONSE DATA FROM ITS ONGOING PHASE 1
CLINICAL STUDY OF ONCR-177, ITS LEAD VIRAL IMMUNOTHERAPY
CANDIDATE, AT SITC 2021
Source text for Eikon: ID:nGNX25QGWD
Further company coverage: ONCR.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Oncorus
See all newsBrief: Oncorus Board Unanimously Approves Its Plan Of Dissolution, Liquidation
Brief: Oncorus Board Appoints Brian Shea As Interim CEO
U.S. STOCKS ON THE MOVE-Ford Motor, Theratechnologies, 3D Systems
Oncorus says no cash beyond Q3, cuts remaining jobs, shares tumble
Brief: Oncorus Announces Workforce Reduction Plan